Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Neurexan for Improving Sleep in Patients with Short-Term Insomnia

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called Neurexan on individuals experiencing short-term insomnia. Short-term insomnia is a condition where people have trouble sleeping for a period of less than three months. The trial aims to see if Neurexan can help improve sleep efficiency, which means how well a person sleeps during the night. Neurexan is a tablet that contains natural ingredients like zincum isovalerianicum, coffea arabica, passiflora incarnata, and avena sativa. These ingredients are used in homeopathic medicine to help with sleep and stress.

Participants in the study will be given either Neurexan or a placebo, which looks like the medication but does not contain any active ingredients. The study will monitor how well participants sleep using a method called polysomnography, which records brain waves, oxygen levels, heart rate, and breathing during sleep. Additionally, participants will report their sleep patterns and daytime performance through questionnaires. The study will also look at stress response by measuring certain markers in the body.

The trial will take place over a period of time, with participants taking the medication daily. The goal is to determine if Neurexan can improve sleep and reduce stress in people with short-term insomnia. This study is exploratory, meaning it is designed to gather more information about how Neurexan works in improving sleep and managing stress. Participants will be closely monitored throughout the study to ensure their safety and to collect accurate data on the effects of the treatment.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    The trial begins with an initial visit where eligibility is confirmed. This includes checking for short-term insomnia as defined by specific criteria.

    Participants must be between 18 and 65 years old, with a body mass index (BMI) between 18.5 and 29.9 kg/m².

  2. Step 2

    Baseline assessment

    Participants undergo a baseline assessment to measure sleep efficiency using polysomnography, a test that records brain waves, oxygen levels, heart rate, and breathing during sleep.

    Participants are required to report their habitual bedtime and time spent in bed.

  3. Step 3

    Treatment phase

    Participants receive either Neurexan tablets or a placebo. Neurexan contains active substances such as zincum isovalerianicum and coffea arabica.

    The medication is taken orally in tablet form. The dosage and frequency are determined by the study protocol.

  4. Step 4

    Follow-up visits

    Participants attend follow-up visits to monitor changes in sleep efficiency and other sleep parameters.

    These visits include further polysomnography tests and assessments of daytime performance and stress response.

  5. Step 5

    Final assessment

    The trial concludes with a final assessment to evaluate the overall effects of the treatment on sleep efficiency and other related outcomes.

    Participants complete sleep questionnaires and diaries to provide subjective feedback on their sleep patterns.

Who can join the trial?

11 criteria

  • The patient must have **short-term insomnia** as defined by the DSM-5 criteria, with symptoms lasting less than 3 months.
  • The patient should have **moderate symptoms** of short-term insomnia, with a score between 8 and 22 on the **Insomnia Severity Index (ISI)**, present for at least one week but not longer than 3 months before the screening visit.
  • The patient should report a **habitual bedtime** between 9:00 PM and 1:00 AM, which is the time they usually try to sleep.
  • The patient should report spending **6 to 9 hours in bed** each night, either sleeping or trying to sleep.
  • The patient must be **18 years or older**, but not older than 65 years.
  • The patient must be **legally competent**, meaning they are able to make their own decisions.
  • The patient must have **signed an informed consent**, agreeing to participate in the study.
  • Females who can have children must agree to use **highly effective or acceptable birth control** methods during the trial. Highly effective methods include hormonal contraception, intrauterine devices, and others. Acceptable methods include condoms and other barrier methods.
  • The patient must have a **Body Mass Index (BMI)** between 18.5 and 29.9 kg/m² at the screening visit. BMI is a measure of body fat based on height and weight.
  • The patient must be able to use a **digital device** like a smartphone, tablet, or laptop.
  • The patient must be able to **speak and read German**.

Who cannot join the trial?

7 criteria

  • Patients with any other sleep disorders besides short-term insomnia cannot participate. This means if you have other sleep problems, you may not be eligible.
  • Individuals with serious medical conditions that could affect sleep or the study results are excluded. This means if you have a major health issue, you might not be able to join.
  • People who are currently taking medications that affect sleep are not allowed to participate. This means if you are on sleep-related medication, you may not qualify.
  • Participants who have a history of drug or alcohol abuse are excluded. This means if you have had problems with drugs or alcohol, you might not be eligible.
  • Women who are pregnant or breastfeeding cannot take part in the study. This means if you are expecting a baby or nursing, you may not be able to join.
  • Individuals who have participated in another clinical trial recently are not allowed. This means if you have been in a different study lately, you might not qualify.
  • People with known allergies to the study medication are excluded. This means if you are allergic to the treatment being tested, you cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Neurexan is a medication being studied for its potential to improve sleep efficiency in people with short-term insomnia. The trial aims to see if taking Neurexan daily can help patients sleep better, as measured by various methods like polysomnography, which records brain waves and other sleep-related data. The study also looks at how Neurexan might affect daytime performance and stress levels, using both scientific measurements and patient feedback.

What is already known about the treatment

Neurexan – Neurexan is administered orally in tablet form. It is currently being studied in clinical trials for its effects on short-term insomnia, with a focus on improving sleep efficiency. The main therapeutic indication for Neurexan is short-term insomnia, where it aims to enhance sleep quality and reduce stress. At the molecular level, Neurexan is believed to work by modulating neurotransmitter activity to promote relaxation and improve sleep patterns. It is classified pharmacologically as a homeopathic remedy, which is often used to address sleep disturbances and stress-related symptoms.

Investigated diseases

Short-Term Insomnia – Short-term insomnia is a sleep disorder characterized by difficulty falling asleep or staying asleep for a brief period, typically lasting a few days to a few weeks. It often occurs due to stress, changes in sleep environment, or disruptions in daily routine. Individuals with short-term insomnia may experience reduced sleep quality, leading to daytime fatigue, irritability, and difficulty concentrating. The condition usually resolves on its own once the underlying cause is addressed or the individual adapts to changes. It is distinct from chronic insomnia, which persists for a longer duration and may require more comprehensive management.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-514391-41-00Protocol codeC2104Estimated enrolment80 patientsSponsorBiologische Heilmittel Heel GmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).